Neurocrine Biosciences to Present at the Citi 15th Annual BioPharma Virtual Conference
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Citi 15th Annual BioPharma Virtual Conference on September 9, 2020, at 12:35 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Citi 15th Annual BioPharma Virtual Conference on September 9, 2020, at 12:35 p.m. ET. CEO Kevin Gorman will deliver the presentation, which will be available via a live webcast on the company's website. A replay of the presentation will be accessible approximately one hour after the event, remaining archived for about a month. Neurocrine is focused on developing treatments for neurological and psychiatric disorders, with several FDA-approved products and ongoing clinical programs.
Details
News Market Reaction – NBIX
The recorded move for NBIX in the trading session of this news was -4.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Citi 15th Annual BioPharma Virtual Conference at 12:35 p.m. ET on Wednesday, September 9, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.
The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, with three pivotal and five mid-stage clinical programs in multiple therapeutic areas. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)
View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-citi-15th-annual-biopharma-virtual-conference-301123291.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.